目的 建立非奈利酮药物利用评价（DUE）标准，为临床合理应用非奈利酮提供参考。方法 参考非奈利酮的说明书、相关指南、专家共识等，运用专家咨询法，从用药指征、用药过程、用药结果3个方面建立非奈利酮的DUE标准。回顾性研究福建医科大学附属南平第一医院2023年4月—2024年12月使用非奈利酮的病历，进行合理用药评价。结果 建立的非奈利酮DUE标准含3级指标，包括一级指标3项，二级指标10项，三级指标26项。共纳入使用非奈利酮的病例406例，合理325例，合理率为80.05%，不合理情况主要为适应证不适宜（4.93%）、起始剂量不适宜（19.70%）和药物相互作用（5.17%）等方面。结论 建立的非奈利酮DUE标准具有较强的科学性、实用性和可行性，可为临床合理用药提供参考依据。

Objective To establish the drugusee valuation (DUE) standard of finerenone, and to provide reference for the rational clinical application of finerenone. Methods Based on the ticagrelor drug label, related guidelines and literature, combined with clinical expert consulation results, DUE standard from three levels (indications, medications, and medication results) was estiblished. The medical records of fenelidone in Nanping First Hospital of Fujian Province from April 2023 to December 2024 were retrospectively studied to evaluate rational drug use. Results The DUE of finerenone included 3 primary indexes, 10 secondary indexes, and 26 tertiary indexes. A total of 406 cases of using finerenone were included, of which the rational rate was 80.05%. The irrational cases were mainly off-label use (4.93%), unreasonable initial dose (19.70%), and drug interaction (5.17%). Conclusion The established DUE standard of finerenone is scientific, practical, and feasible, which can provide reference for clinical rational drug use.

R972

福建省自然科学基金资助项目（2022J011488）